Surrozen, Inc./DE (SRZN) stock
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.61−0.06 (-0.19%)
Close on Nov 13, 2026Market cap $371.53MP/E –Yield –
Surrozen EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Surrozen's EPS for the twelve months ending Sep 30, 2025 was -$8630.02. For fiscal 2025 it was -$32.37. The highest annual figure on record is -$15.56 in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$32.37 | – |
| FY2024 | Dec 31, 2024 | -$21.67 | – |
| FY2023 | Dec 31, 2023 | -$21.33 | – |
| FY2022 | Dec 31, 2022 | -$15.56 | – |
| FY2021 | Dec 31, 2021 | -$33.15 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.41 | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.65 | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.36 | – |
| Q2 FY2025 | Jun 30, 2025 | $2.55 | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.43 | – |
| Q4 FY2024 | Dec 31, 2024 | -$8616.78 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.44 | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.14 | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.68 | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.16 | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.70 | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.00 | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.45 | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.65 | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.35 | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.80 | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.97 | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.05 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?